why choose us

First received: November 01, 2022

Clinical Trial: Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

Study Status: Completed

Recruit Status: RECRUITING

Condition: Parkinson Disease

Study Type: INTERVENTIONAL


Official Title: An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging

Brief Summary: Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease.This study will determine if a lower dose (5 millicuries) would suffice.

Read more